setidegrasib
Phase 3An investigational KRAS G12D protein degrader in a phase 3 comparison with docetaxel for previously treated, progressing KRAS G12D-mutated advanced NSCLC.
← Company library
アステラス製薬
Conducts pharmaceutical R&D, including targeted protein degradation candidates in oncology.
01
Products & pipeline
02
Recent developments
The September 24 release announced the first patient dosed in that phase 3 study; it did not separately specify the dosing date.
03
Experience in official career sources
Official role guide
創薬研究職 — 仕事の内容
Not an individual vacancyObserved 2026-10-04
- Work
- Describes basic and nonclinical research, drug-discovery technologies and research advancing candidates toward clinical development.
- Experience & requirements
- Unconfirmed — The reviewed general role guide does not specify mandatory degree or years of experience.
Information from a role guide does not establish a current vacancy.
Recruitment program
2027年度 新卒入社・博士通年選考
Closed postingObserved 2026-10-04
- Work
- Unconfirmed — The current requirements page shows recruitment has ended; individual advertised duties were not verified.
- Experience & requirements
- Unconfirmed — Detailed eligibility for the closed graduate program is unverified.
Sources & coverage 4
A brief based on selected official material, not an exhaustive product or vacancy list.
- アステラス製薬 企業・研究紹介 ↗アステラス製薬 · Published Date unconfirmed · Sources checked 2026-10-03
- Setidegrasib 第3相 初回患者投与 ↗Astellas · Published 2026-09-24 · Sources checked 2026-10-03
- 創薬研究職 — 仕事の内容 ↗アステラス製薬 · Published Date unconfirmed · Sources checked 2026-10-03
- 2027年度 募集要項 ↗アステラス製薬 · Published Date unconfirmed · Sources checked 2026-10-04